Cytotoxic T cell

Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, January 3, 2024
Quality of life, Leukopenia, URTI, Constipation, Lower respiratory tract infection, IND, Insomnia, CD8, Diarrhea, PD-1, DVT, Anemia, Gastroenteritis, Tremor, Fatigue, Common, CD4, Nausea, Multiple myeloma, Neutropenia, Abdominal pain, Therapy, Lenalidomide, Pharmacokinetics, Weakness, Dizziness, Thrombocytopenia, Cytotoxic T cell, Dexamethasone, Appetite, Periodic breathing, Bortezomib, Toxicity, Back pain, Patient, Safety, Peripheral edema, Deep vein thrombosis, Vomiting, Cough, Rash, Bronchitis

Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date. Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks. In comparison, adverse events in these patients observed during a prior regimen containing Revlimid® included nausea, vomiting, deep vein thrombosis (DVT), upper respiratory tract infections (URTI), anemia, and fatigue. None of the more common side effects of lenalidomide (Revlimid®), which include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor, have been observed with STAR-LLD. Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects. These data suggest that STAR-LLD may prove to be superior in tolerability to oral Revlimid, expanding the number of patients that get the full Revlimid® benefit and improving quality of life.

Key Points: 
  • Patient acceptance of self-administration using the ambulatory pump for lenalidomide delivery has been confirmed in this study.
  • Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date.
  • Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks.
  • Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects.

Aichi Cancer Center and NEC Develop an Efficient Method for Identifying Lung Cancer Antigens and Antigen-Specific T Cells

Retrieved on: 
Tuesday, August 8, 2023
NEC, Tex, Antigen, ICIS, DNA, Society, Gifu University, ICI, SORL1, Spatial analysis, TIL, UMAP, Single-cell analysis, Lung cancer, NEC Corporation of America, NEC Laboratories America, AKT2, CTA, Immunotherapy, Individual, SITC, Research, Gene expression, NSCLC, Cytotoxic T cell, RNA, University of Toyama, TCR, Projection, Figure, TILS, CTAS, Patient, CTL, Knowledge, Society for Immunotherapy of Cancer, Gene, Vaccine, Medical imaging, Cancer

- Aichi Cancer Center and NEC developed a method for efficiently identifying lung cancer antigens (oncology marks) and antigen-specific T cells by combining single-cell analysis (1) of Tumor Infiltrating Lymphocytes (TIL) and NEC's AI-based antigen prediction system.

Key Points: 
  • - Aichi Cancer Center and NEC developed a method for efficiently identifying lung cancer antigens (oncology marks) and antigen-specific T cells by combining single-cell analysis (1) of Tumor Infiltrating Lymphocytes (TIL) and NEC's AI-based antigen prediction system.
  • - Aichi Cancer Center and NEC clarified the characteristics of T cells that specifically recognize antigens.
  • In collaboration with NEC and leading research institutes, the Aichi Cancer Center has developed a procedure for efficiently identifying antigens and antigen-specific T cells using surgical samples from patients with cancer.
  • (2) KK-LC-1 (KitaKyushu Lung Canner antigen-1): Cancer and testis antigens that have been reported to be expressed in cancer.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

Retrieved on: 
Thursday, July 6, 2023
Ohio State University, RLK, TCL, University, Stanford University, Neoplasm, ITK, Cancer, T-cell lymphoma, Cell, Publication, Cytotoxic T cell, Immunotherapy, Preprint, Colon, Interleukin, Patient, Melanoma, Peking University, Cytokine, FDA, Autoimmunity, Pharmaceutical industry, Vaccine, Corvus

BURLINGAME, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data on soquelitinib (formerly known as CPI-818), the Company’s ITK inhibitor product candidate, which highlighted the selective inhibition of ITK to potentially enhance anti-tumor immune response to hematologic and solid tumors and provide a novel approach to cancer immunotherapy.

Key Points: 
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • “This significant scientific report demonstrates the potential of highly selective ITK inhibition, now enabled by soquelitinib.
  • The findings reported indicate that ITK is a novel drug target and its blockade may enhance the body’s immune response to cancer.
  • Led to in vivo anti-tumor activity in several mouse tumor models, including colon, renal, melanoma, B cell and T cell tumors.

Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation

Retrieved on: 
Thursday, June 29, 2023
Long COVID, Infection, Weapon, Antigen, Partnership, Therapy, Semper paratus, Virology, COVID-19, Clinical trial, Cancer, Semper, Multiple sclerosis, Immunotherapy, TVGN, LGST, Acquisition, Transaction, Viral, Cytotoxic T cell, Growth, Immunodeficiency, Health, MPH, Neurology, NYSE, Safety, Vaccine, Pharmaceutical industry, Management, MD

Tevogen Bio, along with its founder, has received broad recognition for its innovative, patient-first approach in the biopharma industry.

Key Points: 
  • Tevogen Bio, along with its founder, has received broad recognition for its innovative, patient-first approach in the biopharma industry.
  • Upon closing of the merger (the “Transaction”), the combined company will be named Tevogen Bio Holdings Inc. (“Tevogen Holdings”).
  • Tevogen Holdings common stock and warrants are expected to be listed on the NYSE under the new ticker symbol “TVGN”.
  • Additionally, the Transaction includes a contingent earnout in the form of additional equity in Tevogen Holdings payable to the Tevogen Bio stockholders and Semper Paratus’ sponsor.

Tevogen Bio will Present Positive Proof-of-Concept Trial Findings at the 5th Annual Allogeneic Cell Therapies Summit in Boston, MA

Retrieved on: 
Monday, May 22, 2023
Science, Biotechnology, Research, Health, COVID-19, Infectious Diseases, Genetics, Clinical Trials, Infection, Weapon, Antigen, Cytokine release syndrome, Omicron, Bio, SARS-CoV-2, Principal investigator, Health status of Asian Americans, Clinical trial, Cancer, Viral, Multimedia, DNP, TVGN, Incidence, Genome, MD, Patient, Thomas Jefferson University Hospital, Viral load, Cytotoxic T cell, Clinical, PCR, Safety, Pharmaceutical industry, Vaccine, Long COVID

Tevogen Bio is pleased to announce that it will present the proof-of-concept clinical trial results of TVGN 489, the company's first clinical product from its ExacTcell platform , at the 5th Annual Allogeneic Therapies Summit in Boston, MA.

Key Points: 
  • Tevogen Bio is pleased to announce that it will present the proof-of-concept clinical trial results of TVGN 489, the company's first clinical product from its ExacTcell platform , at the 5th Annual Allogeneic Therapies Summit in Boston, MA.
  • CD8+ CTLs in ExacTcell based products target multiple and distinct antigens to overcome potential mutational challenges, such as TVGN 489.
  • “We believe that cell therapies are expected to be the norm, not the exception,” said Tevogen CEO Ryan Saadi, M.D., M.P.H.
  • “Tevogen aspires and is designed to be the very first biotech to achieve commercial success and patient affordability through advanced science and efficient business models.”

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

Retrieved on: 
Tuesday, December 20, 2022
CXCR4, Antibody, Alpha-gal, Security (finance), Immunotherapy, TASE, AES, Patient, Multiple myeloma, Cytotoxic T cell, Radiation, Congress, Wilms' tumor, Synergy, Part, COVID-19, FDA, Safety, APC, Pancreatic cancer, PDUFA, Annual report, PDAC, NDA, TEL, Caregiver, Risk, Acquisition, Biomarker, Pharmaceutical industry, Medical imaging, Vaccine, BioLineRx

The maximum tolerated dose was not reached and the recommended dose for part 2 of the study (RP2D) was determined to be up to 200mg.

Key Points: 
  • The maximum tolerated dose was not reached and the recommended dose for part 2 of the study (RP2D) was determined to be up to 200mg.
  • In the dose expansion part 2 of the study, AGI-134 was generally well-tolerated, with treatment-related adverse events being transient and mostly mild to moderate.
  • The Phase 1/2a clinical trial was a multicenter, open-label study, which recruited a total of 38 patients in the UK, Spain and Israel.
  • BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

UC Davis' new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections

Retrieved on: 
Wednesday, August 10, 2022
Liver, Biomedical engineering, Cytotoxic T cell, University of California, Davis, Spleen, Molecular imaging, Physics World, Immune system, Cancer, Radiology, Tissue, Research, SNMMI, UC, PET/CT, Nuclear medicine, Blood, Patient, Bone marrow, COVID-19, Doctor of Philosophy, Lymph, Infection, PET, View, Vaccine, Time-invariant system, CD8, Degenerative disease, Innovation, Health, Society of Nuclear Medicine and Molecular Imaging, Medical imaging

Cytotoxic T cells are key players in the cell-mediated immune response against viral infections.

Key Points: 
  • Cytotoxic T cells are key players in the cell-mediated immune response against viral infections.
  • However, 95% of T cells are in tissues rather than in the blood circulation and are therefore difficult to assess non-invasively.
  • High sensitivity PET imaging using a specific T cell radiotracer offers a new methodology to track tissue concentrations of T cells without invasive sampling.
  • It pushes the boundaries of traditional PET scanners, with an effective sensitivity that is up to 68-fold greater than current commercial PET scanners.

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

Retrieved on: 
Sunday, November 21, 2021
Patient, Senior, CEO, Safety, Greater, HKEX, Partnership, Cancer, Mab, Cytotoxic T cell, Microsatellite instability, Torreya, R, Research, Board, IO, CD152, Fine chemical, Pharmaceutical industry, Vaccine

Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.

Key Points: 
  • Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.
  • CStone will retain the rights to develop and commercialize of CS1002 outside of Greater China.
  • There is only one anti-CTLA-4 monoclonal antibody approved globally, and it is also approved in China.
  • Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan.

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

Retrieved on: 
Sunday, November 21, 2021
Patient, Senior, CEO, Safety, Greater, HKEX, Partnership, Cancer, Mab, Cytotoxic T cell, Microsatellite instability, Torreya, R, Research, Board, IO, CD152, Fine chemical, Pharmaceutical industry, Vaccine

Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.

Key Points: 
  • Hengrui will obtain the exclusive rights for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in Greater China.
  • CStone will retain the rights to develop and commercialize of CS1002 outside of Greater China.
  • There is only one anti-CTLA-4 monoclonal antibody approved globally, and it is also approved in China.
  • Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan.

Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Variants of SARS-CoV-2, Medical specialties, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Zoonoses, Forward-looking statement, Cytotoxic T cell, Biology

They found that one key player in the immune response to SARS-CoV-2the CD8+ T cellremained active against the virus."

Key Points: 
  • They found that one key player in the immune response to SARS-CoV-2the CD8+ T cellremained active against the virus."
  • Each variant has mutations throughout the virus, and, in particular, in the region of the virus' spike protein that it uses to attach to and enter cells.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
  • The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.